Ert Pompe denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies ERT for Pompe Disease on Medical-Necessity Grounds

A medical-necessity denial for enzyme replacement therapy in Pompe disease typically means UnitedHealthcare's reviewer determined that the submitted clinical documentation did not satisfy every criterion in their internal coverage policy — even when the treating physician considers the therapy clearly indicated. Common gaps include: incomplete documentation of diagnostic confirmation, absence of baseline functional measurements, or failure to document disease progression in a way that mirrors the plan's specific policy language.

This is almost always a documentation problem, not a clinical one.

## Why This Denial Is Appealable

Pompe disease is a progressive, life-threatening lysosomal storage disorder with no curative option other than ERT for managing its course. When a patient has confirmed disease — via genetic testing and enzyme assay — and is experiencing measurable functional decline, the medical-necessity standard in virtually every evidence-based policy is met. Denials occur when the chart narrative does not speak the plan's language, not because the patient fails to qualify.

## Federal Appeal Framework

• ERISA §503 (employer-sponsored plans) entitles you to a written, specific denial rationale and a full-and-fair internal appeal.
• ACA §2719 provides access to independent external review by an accredited IRO whose reviewers must apply an evidence-based standard — not the plan's proprietary policy definitions.
• The external-review window is generally within approximately four months of denial notice; verify the exact deadline on your Explanation of Benefits.
• Expedited review is available and strongly recommended given Pompe's irreversible progression: respiratory muscle loss and skeletal muscle damage that occur during a delay cannot be recovered.

## Concrete Appeal Steps

1. Obtain UHC's complete medical policy for ERT in Pompe disease — every criterion will be listed. 2. Have your specialist review the denial rationale against the policy criteria to identify exactly which criterion was flagged as unmet. 3. Assemble the documentation below targeted to the specific gap. 4. Submit an internal appeal; if denied, proceed immediately to external review.

## Documentation to Gather

• Diagnosis confirmation: Genetic test report (identifying pathogenic GAA variants); dried blood spot or leukocyte enzyme assay confirming acid alpha-glucosidase deficiency; biopsy if obtained.
• Disease phenotype and onset documentation: Physician note classifying infantile-onset vs. late-onset, with supporting clinical history.
• Baseline and serial functional measurements: Pulmonary function tests (FVC trend over time), six-minute walk test or other motor assessments, and any hospitalization or respiratory support episodes — documented with dates.
• Demonstrated clinical need: Chart entries showing progressive decline or high risk of rapid deterioration without treatment.
• Prescriber medical-necessity letter: A detailed letter from the treating metabolic specialist or neuromuscular physician that maps each policy criterion to the specific chart finding — by name, date, and result (without fabricating numbers not in the chart).
• Prior-treatment history: If any prior therapies were tried, document dates, outcomes, and reason for transition.

## Criteria-Mapping Structure

Copy each criterion verbatim from UHC's policy. Answer each with the exact chart fact:

| UHC Policy Criterion | Chart Evidence (date + source) | |---|---| | Confirmed GAA deficiency by assay | Enzyme assay report dated [date], result on file | | Genetic confirmation of pathogenic variant | Genetic panel report dated [date] | | Documented functional impairment | FVC trend per pulmonary report dated [date]; 6MWT dated [date] | | Specialist oversight | Treating physician: [name, specialty, institution] |

This table becomes the opening page of your appeal letter.